Harmony Biosciences Holdings, Inc. (HRMY) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Harmony Biosciences’s revenue went from $6M in fiscal 2019 to $868M in fiscal 2025, growth of about 129.2% a year.
Net income in fiscal 2025 was $159M, a net margin of 18.3%; the best year in this period was 2022 with $181M.
Over the twelve months to September 30, 2026, revenue was $989M and net income $179M.
Free cash flow was $348M in fiscal 2025 and positive in 5 of the 7 years shown.
The diluted share count rose 653% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $989M | $868M | $715M | $582M | $438M | $305M | $160M | $6M |
| Gross profit | $732M | $670M | $558M | $461M | $354M | $250M | $132M | $4M |
| Operating income | $219M | $208M | $191M | $192M | $120M | $88M | $17M | -$146M |
| Net income | $179M | $159M | $145M | $129M | $181M | $35M | -$37M | -$152M |
| EPS (diluted) | $3.03 | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 | $-24.07 |
| R&D | $238M | $190M | $146M | $76M | $71M | $30M | $19M | $70M |
| Revenue growth | — | +21.5% | +22.8% | +32.9% | +43.4% | +91.2% | +2564.6% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $323M | $348M | $220M | $219M | $144M | $99M | -$3M | -$75M |
| Capital spending | -$648000 | -$310000 | -$1M | -$312000 | -$172000 | -$298000 | -$2000 | -$149000 |
| Free cash flow | $323M | $348M | $219M | $219M | $144M | $98M | -$3M | -$76M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | $100M | — | — | $167000 | — |
| Stock-based pay | $38M | $45M | $43M | $32M | $26M | $16M | $5M | $10M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $775M | $467M | $353M | $323M | $234M | $229M | $24M |
| Debt | — | $169M | $181M | $196M | $194M | $203M | $194M | $98M |
| Equity | — | $870M | $659M | $467M | $403M | $187M | $97M | -$423M |
| Total assets | — | $1.3B | $999M | $811M | $674M | $433M | $427M | $107M |
| Shares (diluted) | 60M | 59M | 58M | 60M | 61M | 59M | 26M | 8M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.0% | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% |
| Operating margin | 22.2% | 24.0% | 26.7% | 33.0% | 27.5% | 28.7% | 10.6% | -2433.8% |
| Net margin | 18.1% | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2535.1% |
| FCF margin | 32.6% | 40.1% | 30.6% | 37.6% | 33.0% | 32.2% | -1.9% | -1260.8% |
| ROIC | — | 14.8% | 17.2% | 21.5% | 15.9% | 20.8% | 4.6% | — |
| ROE | — | 18.2% | 22.1% | 27.6% | 45.1% | 18.6% | -38.0% | 35.9% |
Frequently asked questions
What is Harmony Biosciences’s annual revenue?
$868M in fiscal 2025 and $989M over the twelve months to September 30, 2026.
How much profit does Harmony Biosciences make?
Net income was $159M in fiscal 2025 (net margin 18.3%).
Is Harmony Biosciences’s revenue growing?
Yes: revenue rose 21.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.